降低风险输卵管卵巢切除术后激素治疗与恶性风险的关系
这项多机构回顾性研究纳入159例携带高外显率致病性变异、已行降低风险输卵管卵巢切除术的女性,其中82例接受激素替代治疗,77例未接受。
要点
- 高危致病性变异携带者行降低风险输卵管卵巢切除术后,激素替代治疗未显著增加恶性肿瘤风险。
- 研究为回顾性设计,样本量有限,激素替代治疗与恶性肿瘤风险的长期关联需进一步验证。
核心结论
- 在高危致病性变异携带者中,降低风险输卵管卵巢切除术后接受激素替代治疗与未接受者相比,后续恶性肿瘤发生率无统计学显著差异。
研究设计与样本
- 多机构回顾性研究,经机构审查委员会批准,在五个学术机构开展。
- 纳入年龄18-51岁、携带一种或多种确诊的高外显率种系致病性变异、已行降低风险输卵管卵巢切除术的女性,排除既往恶性肿瘤患者。
- 共分析159例女性,其中82例接受激素替代治疗(雌激素或孕激素的任何组合),77例未接受。
主要发现
- 两组自降低风险手术起平均随访时间均为6年。
临床怎么用
- 对于携带高危致病性变异、已行降低风险输卵管卵巢切除术的女性,激素替代治疗未显示增加后续恶性肿瘤风险,可作为临床决策参考。
局限性
- 回顾性研究设计,样本量有限(159例),可能存在选择偏倚和混杂因素。
- 部分患者通过电话确认激素使用时长和结局,可能存在信息偏倚。
- 平均随访6年,长期安全性需更长时间随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to assess the association between hormone replacement therapy and the incidence of subsequent malignancies in patients who underwent risk-reducing salpingo-oophorectomy and had mutations predisposing them to Müllerian cancers. METHODS: This Institutional Review Board-approved retrospective study was performed at five academic institutions. Women were included if they were age 18-51 years, had one or more confirmed germline highly penetrant pathogenic variants, and underwent risk-reducing salpingo-oophorectomy. Patients with a prior malignancy were excluded. Clinicodemographic data were collected by chart review. Patients with no documented contact for one year prior to study termination were called to confirm duration of hormone use and occurrence of secondary outcomes. Hormone replacement therapy included any combination of estrogen or progesterone. RESULTS: Data were analyzed for 159 women, of which 82 received hormone replacement therapy and 77 did not. In both groups an average of 6 years since risk reduction had passed. The patients treated with hormone replacement therapy did not have a higher risk of subsequent malignancy than those not treated with hormone replacement therapy (6 out of 82 vs. 7 out of 77, P = .68). Patients who received hormone replacement therapy were younger than those who did not receive hormone replacement therapy (39.0 vs. 43.9 years, P < .01) and were more likely to have undergone other risk reductive procedures including mastectomy and/or hysterectomy, though this difference was not statistically significant (69.5% vs. 55.8%, P = .07). CONCLUSIONS: In this multi-institution retrospective study of data from patients with high-risk variant carriers who underwent risk-reducing salpingo-oophorectomy, there was no statistically significant difference in the incidence of malignancy between women who did and did not receive hormone replacement therapy.
引用
- Mills KA, Joshi TV, West L, et al. Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers? Gynecol Oncol. 2020. PMID: 32143914. doi:10.1016/j.ygyno.2020.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。